December 2, 2022
You are here:  Home  >  Latest news  >  Current Article

MannKind stock shoots up after taking its insulin Down Under


Westlake Village-based biotech MannKind announced a distribution agreement with Australian Medical & Scientific Ltd. for its inhalable insulin product Afrezza May 16. The news sent its stock up more than 6 percent in after-hours trading, after it closed down 3.8 percent to $1.27. "We are excited to partner with AMSL Diabetes to accelerate patients’ access…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.